BioArctic Partner Eisai Reports the MAA Submission to the MHRA for Lecanemab to Treat Early Alzheimer's Disease
Shots:
- The company has submitted an MAA to the MHRA for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril Ab to treat early AD. The MAA was based on the results from the confirmatory P-III study (Clarity AD) & the P-IIb study evaluating lecanemab
- The results showed that patients treated with lecanemab achieved a reduction of clinical decline over PBO after 18mos. The (Clarity AD) study met its 1EPs & 2EPs with highly significant results
- Lecanemab may have the ability to impact disease pathology & slow down the progression of the disease. BioArctic gets the rights to commercialize lecanemab in the Nordic region while Eisai & BioArctic are preparing for joint commercialization in the region
Ref: PRNewswire | Image: BioArctic
Related News:- Eisai and Biogen Report the Health Canada Acceptance of New Drug Submission for Leqembi (lecanemab) to Treat Early Alzheimer's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
